Actavis (ACT) and Valeant Pharmaceuticals (VRX) resolve patent litigation related to the...


Actavis (ACT) and Valeant Pharmaceuticals (VRX) resolve patent litigation related to the former's Abbreviated New Drug Applications for generic versions of Ziana and Zyclara which Actavis now agrees to launch in 2016 and 2019 respectively. Valeant will "receive a share of the economic benefits" from the marketing of the generics. 

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs